此文为优先出版论文,建议参考文献书写格式:冯淑玲, 王凌, 王少明, 庄捷, 齐娟, 于荣国, . CYP2A6~* 4基因多态性对右美托咪定药动学的影响[J/OL]. 中国临床药理学与治疗学, 2018 (12). http://www.cnki.net/kcms/detail/34.1206.R.20190102.1606.018.html

节点文献

CYP2A6~* 4基因多态性对右美托咪定药动学的影响

Effects of CYP2A6~* 4 gene polymorphism on dexmedetomidine pharmacokinetics

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 冯淑玲王凌王少明庄捷齐娟于荣国

【Author】 FENG Shuling;WANG Ling;WANG Shaoming;ZHUANG Jie;QI Juan;YU Rongguo;Department of Pharmacy,Fujian Provincial Hospital;Provincial Clinical College of Fujian Medical University;Second Department of Anesthesiology,Fujian Provincial Hospital;Surgery Intensive Care Unit,Fujian Provincial Hospital;

【机构】 福建省立医院药学部福建医科大学省立临床医学院福建省立医院麻醉二科福建省立医院重症外科

【摘要】 目的:在CYP2A6*4突变频率高的中国人中测定CYP2A6*4等位基因对右美托咪定药代动力学的影响,为临床提供参考。方法:31名手术患者通过静脉泵接受0.5μg/kg右美托咪定后,抽取多个时间点的血样,测定血药浓度以及CYP2A6*4的多态性,并进行统计分析。结果:9名患者为*1/*4或*4/*4,22名患者为*1/*1。主要药代动力学参数如下,曲线下面积(AUC)为(1 396.19±332.47)h·ng·L-1,峰值血药浓度(Cmax)为(495.50±104.90)ng/L,分布容积(V)为(0.68±0.20)L/kg,清除率(CL)为(0.38±0.11)L·h-1·kg-1,分布半衰期(t1/2α)为(0.05±0.01)h,消除半衰期(t1/2β)为(2.53±0.04)h。在CYP2A6*1/*1,*1/*4和*4/*4患者中未发现显著的药代动力学差异。结论:中国患者使用右美托咪定后,t1/2β与公布的一致,但t1/2α,V和CL较低。在制定右美托咪定的精准治疗方案时,可不予考虑CYP2A6*4突变。

【Abstract】 AIM: To determine the dexmedetomidine pharmacokinetics of CYP2A6*4 allele in Chinese patients with high mutation frequency of CYP2A6*4 in order to provide clinical references.METHODS:Thirty-one surgery patients received0.5μg/kg dexmedetomidine via intravenous pump.Their plasma concentrations at multiple time-points and polymorphism of CYP2A6*4 were determined and statistically analyzed.RESULTS:Nine patients were*1/*4 or*4/*4,and 22 patients were*1/*1.The main pharmacokinetic parameters were area under curve(AUC)(1 396.19±332.47)h·ng·L-1,peak blood concentration(Cmax)(495.50±104.90)ng/L,distribution volume(V)(0.68±0.20)L/kg,clearance(CL)(0.38±0.11)L·h-1·kg-1,distribution half-life(t1/2α)(0.05±0.01)h,elimination half-life(t1/2β)(2.53±0.04)h.No significant pharmacokinetic differences were found among CYP2A6*1/*1,*1/*4,and*4/*4 patients.CONCLUSION:In Chinese patients treated with dexmedetomidine,t1/2βis consistent with that published,but t1/2α,V and CL are lower.It is unnecessary to consider the mutation when developing the precision regimen of dexmedetomidine.

  • 【文献出处】 中国临床药理学与治疗学 ,Chinese Journal of Clinical Pharmacology and Therapeutics , 编辑部邮箱 ,2018年12期
  • 【分类号】R969.1
  • 【网络出版时间】2019-01-02 16:06:56
  • 【下载频次】24
节点文献中: 

本文链接的文献网络图示:

本文的引文网络